Agenus Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Robert Benjamin Stein. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Robert Benjamin Stein has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:MDXG / MiMedx Group, Inc. President, Regenerative Med. 317,803
US:PTIX / Protagenic Therapeutics, Inc. Director 150,000
US:AGEN / Agenus Inc. President R&D 100,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Robert Benjamin Stein. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AGEN / Agenus Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AGEN / Agenus Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AGEN / Agenus Inc. Insider Trades
Insider Sales AGEN / Agenus Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AGEN / Agenus Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AGEN / Agenus Inc. Insider Trades
Insider Purchases MDXG / MiMedx Group, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AGEN / Agenus Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MDXG / MiMedx Group, Inc. Insider Trades
Insider Sales MDXG / MiMedx Group, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AGEN / Agenus Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-05-16 MDXG Stein Robert Benjamin 10,365 5.9457 10,365 5.9457 61,627 2 5.6300 -3,272 -5.31
2023-05-15 MDXG Stein Robert Benjamin 3,607 6.1465 3,607 6.1465 22,170
2023-05-10 MDXG Stein Robert Benjamin 5,869 5.9261 5,869 5.9261 34,780
2023-05-04 MDXG Stein Robert Benjamin 51,756 5.3418 51,756 5.3418 276,470
2023-04-25 MDXG Stein Robert Benjamin 5,987 3.7440 5,987 3.7440 22,415
2023-04-11 MDXG Stein Robert Benjamin 5,996 3.3100 5,996 3.3100 19,847
2023-03-07 MDXG Stein Robert Benjamin 12,355 4.2446 12,355 4.2446 52,442
2022-09-13 MDXG Stein Robert Benjamin 8,329 3.4560 8,329 3.4560 28,785
2022-09-12 MDXG Stein Robert Benjamin 19,000 3.4360 19,000 3.4360 65,284
2022-08-12 MDXG Stein Robert Benjamin 8,503 4.0390 8,503 4.0390 34,344
2022-08-04 MDXG Stein Robert Benjamin 19,500 3.6200 19,500 3.6200 70,590
2022-06-28 MDXG Stein Robert Benjamin 14,600 3.4700 14,600 3.4700 50,662
2022-03-08 MDXG Stein Robert Benjamin 11,672 4.8590 11,672 4.8590 56,714
2021-08-16 MDXG Stein Robert Benjamin 9,362 11.8530 9,362 11.8530 110,968

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MDXG / MiMedx Group, Inc. Insider Trades
Insider Purchases PTIX / Protagenic Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AGEN / Agenus Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTIX / Protagenic Therapeutics, Inc. Insider Trades
Insider Sales PTIX / Protagenic Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AGEN / Agenus Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PTIX / Protagenic Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Robert Benjamin Stein as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-05-17 2023-05-16 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -10,365 317,803 -3.16 5.95 -61,627 1,889,561
2023-05-17 2023-05-15 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -3,607 328,168 -1.09 6.15 -22,170 2,017,085
2023-05-12 2023-05-10 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -5,869 331,775 -1.74 5.93 -34,780 1,966,132
2023-05-09 2023-05-04 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -51,756 337,644 -13.29 5.34 -276,470 1,803,627
2023-04-27 2023-04-25 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -5,987 389,400 -1.51 3.74 -22,415 1,457,914
2023-04-13 2023-04-11 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -5,996 395,387 -1.49 3.31 -19,847 1,308,731
2023-03-15 2023-03-13 4 MDXG MIMEDX GROUP, INC.
Common Stock
A - Award 135,065 401,383 50.72 4.62 624,000 1,854,389
2023-03-09 2023-03-07 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -12,355 266,318 -4.43 4.24 -52,442 1,130,413
2022-09-14 2022-09-13 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -8,329 278,673 -2.90 3.46 -28,785 963,094
2022-09-14 2022-09-12 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -19,000 287,002 -6.21 3.44 -65,284 986,139
2022-08-16 2022-08-12 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -8,503 306,002 -2.70 4.04 -34,344 1,235,942
2022-08-08 2022-08-04 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -19,500 314,505 -5.84 3.62 -70,590 1,138,508
2022-06-30 2022-06-28 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -14,600 334,005 -4.19 3.47 -50,662 1,158,997
2022-04-12 2022-04-08 4 MDXG MIMEDX GROUP, INC.
Common Stock
A - Award 178,571 348,605 105.02 4.62 824,998 1,610,555
2022-03-10 2022-03-08 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -11,672 170,034 -6.42 4.86 -56,714 826,195
2021-08-17 2021-08-16 4 MDXG MIMEDX GROUP, INC.
Common Stock
S - Sale -9,362 181,706 -4.90 11.85 -110,968 2,153,761
2021-03-08 2021-03-04 4 MDXG MIMEDX GROUP, INC.
Common Stock
A - Award 109,235 191,068 133.49
2020-08-12 2020-08-10 4 MDXG MIMEDX GROUP, INC.
Common Stock
A - Award 81,833 81,833 6.11 500,000 500,000
2020-02-26 2020-02-21 4 PTIX Protagenic Therapeutics, Inc.\new
PTIX Common stock Options
A - Award 150,000 150,000
2017-10-18 2017-10-16 4 PTIX Protagenic Therapeutics, Inc.\new
Non-Qualified Stock Options (Right to Buy()
A - Award 200,000 200,000
2017-04-04 2017-03-31 4 agen AGENUS INC
Stock Option, Right to Buy
A - Award 100,000 100,000 3.77 377,000 377,000
2016-06-21 2016-06-17 4 ATRN Protagenic Therapeutics, Inc.\new
NSO Stock Option
A - Award 40,000 240,000 20.00 1.25 50,000 300,000
2016-06-16 2016-06-14 4 AGEN AGENUS INC
Restricted Stock Unit
A - Award 34,000 34,000
2016-06-16 2016-06-14 4 AGEN AGENUS INC
Stock Option, right to buy
A - Award 250,000 250,000 4.16 1,040,000 1,040,000
2016-05-13 2016-04-26 4/A AGEN AGENUS INC
Common Stock
D - Sale to Issuer 12,389 20,986 144.11 4.15 51,414 87,092
2016-05-13 2016-04-26 4/A AGEN AGENUS INC
Common Stock
A - Award 33,375 33,375 4.15 138,506 138,506
2016-04-28 2016-04-26 4 agen AGENUS INC
Common Stock
D - Sale to Issuer -12,265 20,776 -37.12 4.15 -50,900 86,220
2016-04-28 2016-04-26 4 agen AGENUS INC
Common Stock
A - Award 33,041 33,041 4.15 137,120 137,120
2015-07-08 2015-07-06 4 AGEN AGENUS INC
Stock Option, right to buy
A - Award 18,750 18,750 5.04 94,500 94,500
2015-02-17 2015-02-12 4 AGEN AGENUS INC
Stock Option, Right to Buy
A - Award 87,500 87,500 5.04 441,000 441,000
2014-02-19 2014-02-14 4 AGEN AGENUS INC
Stock Option, Right to Buy
A - Award 200,000 200,000 3.00 600,000 600,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)